

European Commission formally approves Orphan Drug status to BioDan Allogeneic Skin for use in Epidermolysis Bullosa

Madrid, 16th December 2014

ADMSC-fib is an adipose-derived adult mesenchymal stem cells (ADMSCs) of allogenic origin contained in a fibrin-based bioengineered dermis for topical use and for the treatment of Epidermolysis Bullosa.

ADMSCs have anti-inflammatory, pro-angiogenic, antimicrobial properties and produce therapeutic levels of C7 able to restore skin adhesion. Fibrin is a source of growth factors and is structurally optimized to incorporate into surrounding tissue as it allows for cell invasion by fibroblasts and capillaries for subsequent dermal remodeling.

The decision from the European Commission has been issued today, 16/12/2014, and the designation number is EU/3/14/1407.